Most Popular
-
1
Yoon’s jailed mother-in-law excluded from latest parole list
-
2
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
3
Korea’s homegrown nanosatellite successfully launches into space
-
4
[Pressure points] Leggings in public: Fashion statement or social faux pas?
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
-
5
Nicaragua shuts down Seoul embassy
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
-
6
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
7
SK hynix pledges W20tr to ramp up DRAM production at home
-
8
SNU profs to suspend treatment for one day
-
9
Hybe's multilabel system tested amid conflict with Ador
-
10
Over-50s, men, single-person households take up majority of those filing for bankruptcy
LG Chem launches combination drug for diabetes, dyslipidemia in Korea
By Sohn Ji-youngPublished : Oct. 18, 2017 - 14:14
LG Chem on Wednesday launched Zemiro in South Korea.
The combination tablet simultaneously treats diabetes and dyslipidemia, a condition in which an abnormal amount of lipids exist in the bloodstream.
Developed by LG Chem’s biopharmaceuticals unit, Zemiro is a new combination tablet that merges LG’s diabetes drug Zemiglo -- a Diepeptidyl peptidase-4 inhibitor -- with the lipid reduction drug ingredient rosuvastatin.
The combination tablet simultaneously treats diabetes and dyslipidemia, a condition in which an abnormal amount of lipids exist in the bloodstream.
Developed by LG Chem’s biopharmaceuticals unit, Zemiro is a new combination tablet that merges LG’s diabetes drug Zemiglo -- a Diepeptidyl peptidase-4 inhibitor -- with the lipid reduction drug ingredient rosuvastatin.
Patients who previously had to take two separate drugs can now take a single tablet of Zemiro and save more than 25 percent by receiving higher insurance benefits, LG Chem said.
Zemiro is the first combination drug of its kind to be approved and launched in Korea. Merck & Co., known as MSD outside the US and Canada, also has a similar combination drug that was approved by the US Food and Drug Administration in 2011 -- Juvisync.
However, MSD’s Juvisync is currently unavailable in Korea, making Zemiro the only diabetes drug combining a DPP-4 inhibitor with a statin drug, according to LG Chem.
By Sohn Ji-young (jys@heraldcorp.com)
